Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 5/20 | 0.73 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12626220 | 0.84 | HCRTR1 (0.72) | HCRTR2HCRTR1ALDH1A1L3MBTL1USP2 | |
| SCHEMBL12621885 | 0.84 | HCRTR1 (0.53) | HCRTR2HCRTR1ALDH1A1L3MBTL1MAPT | |
| SCHEMBL25493808 | 0.81 | L3MBTL1 (0.53) | HCRTR2HCRTR1ALDH1A1L3MBTL1USP2 | |
| SCHEMBL12622076 | 0.80 | L3MBTL1 (0.52) | HCRTR2HCRTR1ALDH1A1L3MBTL1USP2 | |
| SCHEMBL12623931 | 0.79 | HCRTR1 (0.48) | HCRTR2HCRTR1ALDH1A1L3MBTL1 | |
| SCHEMBL12626093 | 0.77 | L3MBTL1 (0.54) | HCRTR2HCRTR1L3MBTL1USP2MAPT | |
| SCHEMBL12626141 | 0.77 | L3MBTL1 (0.65) | HCRTR2HCRTR1ALDH1A1L3MBTL1USP2 | |
| SCHEMBL18061825 | 0.76 | L3MBTL1 (0.48) | HCRTR2HCRTR1ALDH1A1L3MBTL1 | |
| SCHEMBL15426005 | 0.76 | HCRTR1 (0.52) | HCRTR2HCRTR1ALDH1A1L3MBTL1USP2 | |
| SCHEMBL15425990 | 0.74 | L3MBTL1 (0.67) | ALDH1A1L3MBTL1USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661580-B2 | Method of inhibiting tau phosphorylation | CASSAVA SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-10017736-B2 | Method of inhibiting tau phosphorylation | PAIN THERAPEUTICS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-9500640-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9433604-B2 | Method for inhibiting growth of cancer cells | PAIN THERAPEUTICS INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9354223-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150148318-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | PAIN THERAPEUTICS, INC. | 2015-05-28 | — | — | US | disclosed |
| US-20140017699-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | CASSAVA SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
| US-20140017698-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | WANG HOAU-YAN (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018341-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | CASSAVA SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
| US-8580809-B2 | Filamin A-binding anti-inflammatory analgesic | PAIN THERAPEUTICS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580808-B2 | Filamin A-binding anti-inflammatory analgesic | Pain Therapeutic, Inc. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20110105484-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
| US-20110105547-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105484-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | FLNA, FLNB, OPRK1 | HCRTR2 3420/4885HCRTR1 3537/4885ALDH1A1 2702/4885 |
| US-20110105547-A1 | FILAMIN A-BINDING ANTI-INFLAMMATORY ANALGESIC | FLNA, FLNB, OPRK1 | HCRTR2 3420/4885HCRTR1 3537/4885ALDH1A1 2702/4885 |
| US-20140018341-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | FLNA, FLNB, MAPT | HCRTR2 3501/4885HCRTR1 2888/4885ALDH1A1 4388/4885 |
| US-11661580-B2 | Method of inhibiting tau phosphorylation | FLNA, FLNB, MAPT | HCRTR2 3501/4885HCRTR1 2888/4885ALDH1A1 4388/4885 |
| US-10017736-B2 | Method of inhibiting tau phosphorylation | FLNA, FLNB, MAPT | HCRTR2 3501/4885HCRTR1 2888/4885ALDH1A1 4388/4885 |
| US-20150148318-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | FLNA, FLNB, FSCN1 | HCRTR2 3778/4885HCRTR1 3430/4885ALDH1A1 3552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.